UroGen Pharma to Participate at Upcoming Investor Conferences

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/01/2024 - 08:00 AM EST

– Guggenheim 6th Annual Biotechnology Conference –

– Oppenheimer 34th Annual Healthcare Life Sciences Conference –

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in February:

Guggenheim 6th Annual Biotechnology Conference – February 7-8, 2024
Fireside Chat: February 8, 2024 at 11:00 AM ET
Format: 1x1 meetings
Location: New York, NY
Webcast Link: https://guggenheim.metameetings.net/events/guggenheimbiotech24/sessions/50270-urogen-pharma-ltd/webcast

Oppenheimer 34th Annual Healthcare Life Sciences Conference – February 13-14, 2024
Presentation: February 13, 2024 at 12:00 PM ET
Format: Virtual
Webcast Link: https://wsw.com/webcast/oppenheimer33/register.aspx?conf=oppenheimer33&page=urgn&url=https://wsw.com/webcast/oppenheimer33/urgn/2806968

A webcast from both conferences will also be available via the Investors section of UroGen’s website, www.urogen.com. A replay of the webcast will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.